Biodesix

Update in progress

BDSX (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryDiagnostics & Research

Biodesix, Inc. is a diagnostic solutions company focused on blood-based lung cancer tests. Nodify Lung Nodule Risk Assessment helps assess cancer risk and guide treatment for suspicious nodules. GeneStrat ddPCR and NGS, along with VeriStrat, support diagnosis by detecting tumor mutations and immune status to inform therapy. The company also provides translational research, assay design, development, regulatory and logistical services, and operates laboratories. Based in Louisville, Colorado, it originated as Elston Technologies, renamed Biodesix in 2006.

Company score

Sentiment: 0.10; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.05; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive